A Phase 3 interventional study of VARIVAX™ in Varicella, sponsored by Merck Sharp & Dohme LLC. Completed at 5 sites in Russian Federation. Open to participants aged 12 Months to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-04-06.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing Chickenpox Vaccine in Chickenpox — 5 open to participants now, 7 under way, 4 of them phase 3. Chickenpox Vaccine · Chickenpox.
Among the 36 studies testing Chickenpox Vaccine in Chickenpox, this one is the 25th largest by enrollment, is the only one that started in 2019, is one of 12 in phase 3, and was the 24th registered.
180 studies on the registry are indexed under Chickenpox; 28 are open to participants now.
Browse Chickenpox studies →5 of the 36 studies testing Chickenpox Vaccine in Chickenpox are open now, in 7 countries. Recruiting first, the newest first:
SK Bioscience Co., Ltd. · Sites in Honduras, Philippines, Korea, Republic of and 1 more country
Ages 12 mo–12 yrs · Healthy volunteers
University Hospital, Geneva · Sites in Switzerland
Ages up to 18
Sinovac (Dalian) Vaccine Technology Co., Ltd. · Sites in China
Ages 8–16 · Healthy volunteers
Sinovac (Dalian) Vaccine Technology Co., Ltd. · Sites in China
Ages 1–17 · Healthy volunteers
Sinovac (Dalian) Vaccine Technology Co., Ltd. · Sites in Vietnam
Ages 1–12 · Healthy volunteers
By country, each count listing its studies:
Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →
Of the 16 Chickenpox studies recruiting now, 3 (19%) set no upper age limit and 13 (81%) stop at 75 or younger; 12 take children under 18; 13 take healthy volunteers.
This study: 12 Months to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 6 · Phase 3 14 · Phase 4 14
First in 1998; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 150 is below the median of 475 across 149 interventional studies indexed under Chickenpox.
Median enrollment 404 across the 36 interventional studies. Of the 20 that completed or were terminated, 5 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 36 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
28 studies in Chickenpox by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 27 finished, 19 (70%) have results posted.
Among the 28 studies in Chickenpox by Merck & Co., Inc, this one is the 21st largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2019, is one of 21 in phase 3, and was the 28th registered.
Merck & Co., Inc’s Chickenpox studies by the year they started, since 1995.
1 of the studies testing Chickenpox Vaccine in Chickenpox that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07415252Phase 3SK Bioscience Co., Ltd.SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years | 2027-02-13 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies testing Chickenpox Vaccine in Chickenpox, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 28 in Chickenpox:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate the immunogenicity and safety of VARIVAX™ vaccine in healthy Russian children, adolescents, and adults. No formal hypothesis was tested.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants will receive one dose subcutaneous (SC) VARIVAX™ on Day 1. Adult participants and adolescent participants 13 years and older will also receive a second SC dose VARIVAX™ on Day 43.
Biological: VARIVAX™
VARIVAX™ administered by SC injection as 0.5 mL Varicella Virus Vaccine Live in sterile suspension on Day 1 (all participants) and Day 43 (adult and adolescent participants).
Varicella Zoster Virus (VZV) Antibody Response Rate at 6 Weeks Post Last Vaccination in Participants Who Were Seronegative at Baseline
VZV antibody titers were measured using a glycoprotein enzyme-linked immunosorbent assay (gpELISA). The VZV antibody response rate was defined as the percentage of participants with a post-vaccination VZV antibody titer ≥5 gpELISA units/mL for participants whose baseline VZV antibody titer was \<1.25 gpELISA units/mL. VZV antibody response rate was reported for all study arms at 6 weeks post last vaccination (Vaccination 1 for children and Vaccination 2 for adults and adolescents) for participants who were seronegative to VZW at baseline.
Time frame: Adults and Adolescents: 6 weeks post Vaccination 2 (up to approximately 86 days), Children: 6 weeks post Vaccination 1 (up to approximately 43 days)
Geometric Mean Titers (GMTs) of VZV Antibodies at 6 Weeks Post Last Vaccination in Participants Who Were Seronegative at Baseline
GMTs of VZV antibodies were measured post-vaccination using a gpELISA. GMT was calculated at each time point by taking the log of the titers, averaging over all participants values, and then back-transforming to the original scale. GMT was reported for all study arms at 6 weeks post last vaccination (Vaccination 1 for children and Vaccination 2 for adults and adolescents) for participants who were seronegative to VZW at baseline.
Time frame: Adults and Adolescents: 6 weeks post Vaccination 2 (up to approximately 86 days), Children: 6 weeks post Vaccination 1 (up to approximately 43 days)
VZV Antibody Seroconversion Rate at 6 Weeks Post Last Vaccination in Participants Who Were Seronegative at Baseline
VZV antibody levels were measured using a gpELISA. The VZW antibody seroconversion rate was defined as the percentage of participants with VZV antibodies ≥1.25 gpELISA units/mL in participants with a baseline VZV antibody titer \<1.25 gpELISA units/mL. VZW antibody seroconversion was reported for all study arms at 6 weeks post last vaccination (Vaccination 1 for children and Vaccination 2 for adults and adolescents) for participants who were seronegative to VZW at baseline.
Time frame: Adults and Adolescents: 6 weeks post Vaccination 2 (up to approximately 86 days), Children: 6 weeks post Vaccination 1 (up to approximately 43 days)
GMTs of VZV Antibodies at Day 1 and 6 Weeks Post Last Vaccination in Participants Who Were Seropositive at Baseline
GMTs of VZV antibodies were measured post-vaccination using a gpELISA. GMT was calculated at each time point by taking the log of the titers, averaging over all participants values, and then back-transforming to the original scale. GMT was reported for all study arms at 6 weeks post last vaccination (Vaccination 1 for children and Vaccination 2 for adults and adolescents) for participants who were seropositive to VZW at baseline. Per protocol, confidence intervals (CIs) were only calculated when there were at least 5 participants who were seropositive in a treatment group.
Time frame: Day 1 (Baseline), 6 weeks post last vaccination (Day 43 for children and Day 84 for adults and adolescents)
Geometric Mean Fold Rise (GMFR) in VZV Antibody Titers From Day 1 to 6 Weeks Post Last Vaccination in Participants Who Were Seropositive at Baseline
GMTs were measured using a gpELISA. For participants who were seropositive at baseline (baseline VZV antibody titer ≥1.25 gpELISA units/mL), the GMFR was calculated as the ratio of the VZV GMT at 6 weeks post last vaccination to the VZV GMT at Day 1 (baseline). The GMFR from Day 1 was reported for all study arms at 6 weeks post last vaccination (Vaccination 1 for children and Vaccination 2 for adults and adolescents) for participants who were seropositive to VZW at baseline. Per protocol, CIs were only calculated when there were at least 5 participants who were seropositive in a treatment group.
Time frame: Day 1 (Baseline), 6 weeks post last vaccination (Day 43 for children and Day 84 for adults and adolescents)
Percentage of Participants With ≥4-Fold Rise in Antibody Titers From Day 1 to 6 Weeks Post Last Vaccination Among Participants Who Were Seropositive at Baseline
GMTs were measured using a gpELISA. For participants who were seropositive at baseline (baseline VZV antibody titer ≥1.25 gpELISA units/mL), the percentage of participants with a ≥4-fold rise in VZV antibody titer from Day 1 (baseline) to post-vaccination was assessed and reported for all study arms at 6 weeks post last vaccination (Vaccination 1 for children and Vaccination 2 for adults and adolescents). Per protocol, CIs were only calculated when there were at least 5 participants who were seropositive in a treatment group.
Time frame: Day 1 (Baseline), 6 weeks post last vaccination (Day 43 for children and Day 84 for adults and adolescents)
Percentage of Participants With Solicited Injection-Site Adverse Events (AEs) Post-Vaccination 1
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs, which included erythema, pain, and swelling, were recorded on a Vaccine Report Card (VRC). The percentage of participants who experienced solicited injection-site AEs after Vaccination 1 (up to approximately 5 days post-vaccination) was summarized for all study arms.
Time frame: Up to approximately 5 days post-Vaccination 1
Percentage of Participants With Solicited Injection-Site AEs Post-Vaccination 2
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs, which included erythema, pain, and swelling, were recorded on a VRC. The percentage of participants who experienced solicited injection-site AEs after Vaccination 2 (up to approximately 5 days post-vaccination) was summarized for all study arms receiving a second vaccination (adults and adolescents).
Time frame: Up to approximately 5 days post-Vaccination 2 (up to approximately 48 days)
Percentage of Participants With Unsolicited Injection-Site AEs Post-Vaccination 1
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Unsolicited injection-site AEs were recorded on a VRC. The percentage of participants who experienced unsolicited injection-site AEs after Vaccination 1 (up to approximately 42 days post-vaccination) was summarized for all study arms.
Time frame: Up to approximately 42 days post-Vaccination 1
Percentage of Participants With Unsolicited Injection-Site AEs Post-Vaccination 2
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Unsolicited injection-site AEs were recorded on a VRC. The percentage of participants who experienced unsolicited injection-site AEs after Vaccination 2 (up to approximately 42 days post-vaccination) was summarized for all study arms receiving a second vaccination (adults and adolescents).
Time frame: Up to approximately 42 days post-Vaccination 2 (up to approximately 86 days)
Percentage of Participants With Elevated Temperature Post-Vaccination 1
The participant's temperature was taken in the evening after Vaccination 1 and daily through Day 28, and was recorded on a VRC. An elevated temperature was defined as ≥39.0 °C (102.2 °F). The percentage of participants with elevated temperature after Vaccination 1 (up to approximately 28 days post-vaccination) was summarized for all study arms.
Time frame: Up to 28 days post-Vaccination 1
Percentage of Participants With Elevated Temperature Post-Vaccination 2
The participant's temperature was taken in the evening after Vaccination 2 and daily through Day 28, and was recorded on a VRC. An elevated temperature was defined as ≥39.0 °C (102.2 °F). The percentage of participants with elevated temperature after Vaccination 2 (up to approximately 28 days post-vaccination) was summarized for all study arms receiving a second vaccination (adults and adolescents).
Time frame: Up to 28 days post-Vaccination 2 (up to approximately 71 days)
Percentage of Participants With Varicella- and Herpes Zoster-Like Rashes Post-Vaccination 1
The development of varicella-like and herpes zoster-like rashes was recorded on a VRC. The percentage of participants who experienced varicella-like and herpes zoster-like rashes after Vaccination 1 (up to approximately 42 days post-vaccination) was summarized for all study arms.
Time frame: Up to approximately 42 days post-Vaccination 1
Percentage of Participants With Varicella- and Herpes Zoster-Like Rashes Post-Vaccination 2
The development of varicella-like and herpes zoster-like rashes was recorded on a VRC. The percentage of participants who experienced varicella-like and herpes zoster-like rashes after Vaccination 2 (up to approximately 42 days post-vaccination) was summarized for all study arms receiving a second vaccination (adults and adolescents).
Time frame: Up to approximately 42 days post-Vaccination 2 (up to approximately 86 days)
Percentage of Participants With Systemic AEs Post-Vaccination 1
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A systemic AE was defined as any non-injection-site AE. Systemic AEs were recorded on a VRC. The percentage of participants who experienced a systemic AE after Vaccination 1 (up to approximately 42 days post-vaccination) was summarized for all study arms.
Time frame: Up to approximately 42 days post-Vaccination 1
Percentage of Participants With Systemic AEs Post-Vaccination 2
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A systemic AE was defined as any non-injection-site AE. Systemic AEs were recorded on a VRC. The percentage of participants who experienced a systemic AE after Vaccination 2 (up to approximately 42 days post-vaccination) was summarized for all study arms receiving a second vaccination (adults and adolescents).
Time frame: Up to approximately 42 days post-Vaccination 2 (up to approximately 86 days)
Percentage of Participants With 1 or More Serious Adverse Events (SAEs) Post-Vaccination 1 or Post-Vaccination 2
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was an AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or another important medical event. The percentage of participants who experienced one or more SAEs after either vaccination (up to approximately 42 days post-vaccination) was summarized for all study arms.
Time frame: Up to 42 days post-Vaccination 1 or post-Vaccination 2 (up to approximately 86 days)
Percentage of Participants With Vaccine-Related SAEs Post-Vaccination 1 or Post-Vaccination 2
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A vaccine-related SAE was an AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or another important medical event, that was considered at least possibly related to the study vaccine. The percentage of participants who experienced one or more vaccine-related SAEs after either vaccination (up to approximately 42 days post-vaccination) was summarized for all study arms.
Time frame: Up to 42 days post-Vaccination 1 or post-Vaccination 2 (up to approximately 86 days)
Percentage of Participants With Vaccine-Related Death Post-Vaccination 1 or Post-Vaccination 2
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A vaccine-related SAE was an AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or another important medical event, that was considered at least possibly related to the study vaccine. The percentage of participants who experienced a vaccine-related SAE that resulted in death after either vaccination (up to approximately 42 days post-vaccination) was summarized for all study arms.
Time frame: Up to 42 days post-Vaccination 1 or post-Vaccination 2 (up to approximately 86 days)
This study enrolled healthy Russians aged 12 months and older. Additional inclusion criteria applied.
| Milestone | VARIVAX Adults (18 to 75 Years) | VARIVAX™ Adolescents 13 to 17 Years of Age | VARIVAX™ Children 7 to 12 Years of Age | VARIVAX™ Children 12 Months to 6 Years of Age |
|---|---|---|---|---|
| Started | 50 | 30 | 33 | 37 |
| Vaccination 1 | 50 | 30 | 33 | 37 |
| Vaccination 2 | 49 | 30 | 0 | 0 |
| Completed | 49 | 30 | 33 | 37 |
| Not completed | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 |
VZV antibody titers were measured using a glycoprotein enzyme-linked immunosorbent assay (gpELISA). The VZV antibody response rate was defined as the percentage of participants with a post-vaccination VZV antibody titer ≥5 gpELISA units/mL for participants whose baseline VZV antibody titer was \<1.25 gpELISA units/mL. VZV antibody response rate was reported for all study arms at 6 weeks post last vaccination (Vaccination 1 for children and Vaccination 2 for adults and adolescents) for participants who were seronegative to VZW at baseline.
| Percentage of participants | VARIVAX Adults (18 to 75 Years) | VARIVAX™ Adolescents 13 to 17 Years of Age | VARIVAX™ Children 7 to 12 Years of Age | VARIVAX™ Children 12 Months to 6 Years of Age |
|---|---|---|---|---|
| Varicella Zoster Virus (VZV) Antibody Response Rate at 6 Weeks Post Last Vaccination in Participants Who Were Seronegative at Baseline | 100.0 (86.8 to 100.0) | 100.0 (81.5 to 100.0) | 95.5 (77.2 to 99.9) | 100.0 (89.7 to 100.0) |
GMTs of VZV antibodies were measured post-vaccination using a gpELISA. GMT was calculated at each time point by taking the log of the titers, averaging over all participants values, and then back-transforming to the original scale. GMT was reported for all study arms at 6 weeks post last vaccination (Vaccination 1 for children and Vaccination 2 for adults and adolescents) for participants who were seronegative to VZW at baseline.
| gpELISA units/mL | VARIVAX Adults (18 to 75 Years) | VARIVAX™ Adolescents 13 to 17 Years of Age | VARIVAX™ Children 7 to 12 Years of Age | VARIVAX™ Children 12 Months to 6 Years of Age |
|---|---|---|---|---|
| Geometric Mean Titers (GMTs) of VZV Antibodies at 6 Weeks Post Last Vaccination in Participants Who Were Seronegative at Baseline | 70.7 ± 47.9 | 78.6 ± 46.5 | 11.3 ± 7.3 | 13.9 ± 11.2 |
VZV antibody levels were measured using a gpELISA. The VZW antibody seroconversion rate was defined as the percentage of participants with VZV antibodies ≥1.25 gpELISA units/mL in participants with a baseline VZV antibody titer \<1.25 gpELISA units/mL. VZW antibody seroconversion was reported for all study arms at 6 weeks post last vaccination (Vaccination 1 for children and Vaccination 2 for adults and adolescents) for participants who were seronegative to VZW at baseline.
| Percentage of participants | VARIVAX Adults (18 to 75 Years) | VARIVAX™ Adolescents 13 to 17 Years of Age | VARIVAX™ Children 7 to 12 Years of Age | VARIVAX™ Children 12 Months to 6 Years of Age |
|---|---|---|---|---|
| VZV Antibody Seroconversion Rate at 6 Weeks Post Last Vaccination in Participants Who Were Seronegative at Baseline | 100.0 ± 86.8 | 100.0 ± 81.5 | 95.5 ± 77.2 | 100.0 ± 89.7 |
GMTs of VZV antibodies were measured post-vaccination using a gpELISA. GMT was calculated at each time point by taking the log of the titers, averaging over all participants values, and then back-transforming to the original scale. GMT was reported for all study arms at 6 weeks post last vaccination (Vaccination 1 for children and Vaccination 2 for adults and adolescents) for participants who were seropositive to VZW at baseline. Per protocol, confidence intervals (CIs) were only calculated when there were at least 5 participants who were seropositive in a treatment group.
| gpELISA units/mL | VARIVAX Adults (18 to 75 Years) | VARIVAX™ Adolescents 13 to 17 Years of Age | VARIVAX™ Children 7 to 12 Years of Age | VARIVAX™ Children 12 Months to 6 Years of Age |
|---|---|---|---|---|
| Day 1 (Baseline) | 71.1 (31.4 to 161.2) | 13.4 (5.8 to 31.0) | 24.8 (7.2 to 85.5) | 4.2 (NA to NA) |
| Post Last Vaccination | 216.7 (132.8 to 353.6) | 151.7 (92.5 to 248.6) | 125.0 (37.9 to 411.7) | 47.6 (NA to NA) |
GMTs were measured using a gpELISA. For participants who were seropositive at baseline (baseline VZV antibody titer ≥1.25 gpELISA units/mL), the GMFR was calculated as the ratio of the VZV GMT at 6 weeks post last vaccination to the VZV GMT at Day 1 (baseline). The GMFR from Day 1 was reported for all study arms at 6 weeks post last vaccination (Vaccination 1 for children and Vaccination 2 for adults and adolescents) for participants who were seropositive to VZW at baseline. Per protocol, CIs were only calculated when there were at least 5 participants who were seropositive in a treatment group.
| Ratio | VARIVAX Adults (18 to 75 Years) | VARIVAX™ Adolescents 13 to 17 Years of Age | VARIVAX™ Children 7 to 12 Years of Age | VARIVAX™ Children 12 Months to 6 Years of Age |
|---|---|---|---|---|
| Geometric Mean Fold Rise (GMFR) in VZV Antibody Titers From Day 1 to 6 Weeks Post Last Vaccination in Participants Who Were Seropositive at Baseline | 3.0 (2.0 to 4.8) | 11.3 (4.6 to 27.5) | 5.0 (2.6 to 9.7) | 11.2 (NA to NA) |
GMTs were measured using a gpELISA. For participants who were seropositive at baseline (baseline VZV antibody titer ≥1.25 gpELISA units/mL), the percentage of participants with a ≥4-fold rise in VZV antibody titer from Day 1 (baseline) to post-vaccination was assessed and reported for all study arms at 6 weeks post last vaccination (Vaccination 1 for children and Vaccination 2 for adults and adolescents). Per protocol, CIs were only calculated when there were at least 5 participants who were seropositive in a treatment group.
| Percentage of participants | VARIVAX Adults (18 to 75 Years) | VARIVAX™ Adolescents 13 to 17 Years of Age | VARIVAX™ Children 7 to 12 Years of Age | VARIVAX™ Children 12 Months to 6 Years of Age |
|---|---|---|---|---|
| Percentage of Participants With ≥4-Fold Rise in Antibody Titers From Day 1 to 6 Weeks Post Last Vaccination Among Participants Who Were Seropositive at Baseline | 60.9 (38.5 to 80.3) | 66.7 (34.9 to 90.1) | 54.5 (23.4 to 83.3) | 100.0 (NA to NA) |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs, which included erythema, pain, and swelling, were recorded on a Vaccine Report Card (VRC). The percentage of participants who experienced solicited injection-site AEs after Vaccination 1 (up to approximately 5 days post-vaccination) was summarized for all study arms.
| Percentage of participants | VARIVAX Adults (18 to 75 Years) | VARIVAX™ Adolescents 13 to 17 Years of Age | VARIVAX™ Children 7 to 12 Years of Age | VARIVAX™ Children 12 Months to 6 Years of Age |
|---|---|---|---|---|
| Injection-site erythema | 16.0 | 3.3 | 3.0 | 0.0 |
| Injection-site pain | 40.0 | 23.3 | 30.3 | 13.5 |
| Injection-site swelling | 10.0 | 0.0 | 3.0 | 0.0 |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs, which included erythema, pain, and swelling, were recorded on a VRC. The percentage of participants who experienced solicited injection-site AEs after Vaccination 2 (up to approximately 5 days post-vaccination) was summarized for all study arms receiving a second vaccination (adults and adolescents).
| Percentage of participants | VARIVAX Adults (18 to 75 Years) | VARIVAX™ Adolescents 13 to 17 Years of Age | VARIVAX™ Children 7 to 12 Years of Age | VARIVAX™ Children 12 Months to 6 Years of Age |
|---|---|---|---|---|
| Injection-site erythema | 18.4 | 0 | — | — |
| Injection-site pain | 49.0 | 23.3 | — | — |
| Injection-site swelling | 8.2 | 3.3 | — | — |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Unsolicited injection-site AEs were recorded on a VRC. The percentage of participants who experienced unsolicited injection-site AEs after Vaccination 1 (up to approximately 42 days post-vaccination) was summarized for all study arms.
| Percentage of participants | VARIVAX Adults (18 to 75 Years) | VARIVAX™ Adolescents 13 to 17 Years of Age | VARIVAX™ Children 7 to 12 Years of Age | VARIVAX™ Children 12 Months to 6 Years of Age |
|---|---|---|---|---|
| Percentage of Participants With Unsolicited Injection-Site AEs Post-Vaccination 1 | 2.0 | 3.3 | 0.0 | 5.4 |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Unsolicited injection-site AEs were recorded on a VRC. The percentage of participants who experienced unsolicited injection-site AEs after Vaccination 2 (up to approximately 42 days post-vaccination) was summarized for all study arms receiving a second vaccination (adults and adolescents).
| Percentage of participants | VARIVAX Adults (18 to 75 Years) | VARIVAX™ Adolescents 13 to 17 Years of Age | VARIVAX™ Children 7 to 12 Years of Age | VARIVAX™ Children 12 Months to 6 Years of Age |
|---|---|---|---|---|
| Percentage of Participants With Unsolicited Injection-Site AEs Post-Vaccination 2 | 0.0 | 0.0 | — | — |
The participant's temperature was taken in the evening after Vaccination 1 and daily through Day 28, and was recorded on a VRC. An elevated temperature was defined as ≥39.0 °C (102.2 °F). The percentage of participants with elevated temperature after Vaccination 1 (up to approximately 28 days post-vaccination) was summarized for all study arms.
| Percentage of participants | VARIVAX Adults (18 to 75 Years) | VARIVAX™ Adolescents 13 to 17 Years of Age | VARIVAX™ Children 7 to 12 Years of Age | VARIVAX™ Children 12 Months to 6 Years of Age |
|---|---|---|---|---|
| Percentage of Participants With Elevated Temperature Post-Vaccination 1 | 2.0 | 0.0 | 3.0 | 8.1 |
The participant's temperature was taken in the evening after Vaccination 2 and daily through Day 28, and was recorded on a VRC. An elevated temperature was defined as ≥39.0 °C (102.2 °F). The percentage of participants with elevated temperature after Vaccination 2 (up to approximately 28 days post-vaccination) was summarized for all study arms receiving a second vaccination (adults and adolescents).
| Percentage of participants | VARIVAX Adults (18 to 75 Years) | VARIVAX™ Adolescents 13 to 17 Years of Age | VARIVAX™ Children 7 to 12 Years of Age | VARIVAX™ Children 12 Months to 6 Years of Age |
|---|---|---|---|---|
| Percentage of Participants With Elevated Temperature Post-Vaccination 2 | 0.0 | 0.0 | — | — |
The development of varicella-like and herpes zoster-like rashes was recorded on a VRC. The percentage of participants who experienced varicella-like and herpes zoster-like rashes after Vaccination 1 (up to approximately 42 days post-vaccination) was summarized for all study arms.
| Percentage of participants | VARIVAX Adults (18 to 75 Years) | VARIVAX™ Adolescents 13 to 17 Years of Age | VARIVAX™ Children 7 to 12 Years of Age | VARIVAX™ Children 12 Months to 6 Years of Age |
|---|---|---|---|---|
| Varicella-like rash | 6.0 | 0.0 | 6.1 | 2.7 |
| Herpes zoster-like rash | 0.0 | 0.0 | 0.0 | 0.0 |
The development of varicella-like and herpes zoster-like rashes was recorded on a VRC. The percentage of participants who experienced varicella-like and herpes zoster-like rashes after Vaccination 2 (up to approximately 42 days post-vaccination) was summarized for all study arms receiving a second vaccination (adults and adolescents).
| Percentage of participants | VARIVAX Adults (18 to 75 Years) | VARIVAX™ Adolescents 13 to 17 Years of Age | VARIVAX™ Children 7 to 12 Years of Age | VARIVAX™ Children 12 Months to 6 Years of Age |
|---|---|---|---|---|
| Percentage of Participants With Varicella- and Herpes Zoster-Like Rashes Post-Vaccination 2 | 2.0 | 0.0 | — | — |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A systemic AE was defined as any non-injection-site AE. Systemic AEs were recorded on a VRC. The percentage of participants who experienced a systemic AE after Vaccination 1 (up to approximately 42 days post-vaccination) was summarized for all study arms.
| Percentage of participants | VARIVAX Adults (18 to 75 Years) | VARIVAX™ Adolescents 13 to 17 Years of Age | VARIVAX™ Children 7 to 12 Years of Age | VARIVAX™ Children 12 Months to 6 Years of Age |
|---|---|---|---|---|
| Percentage of Participants With Systemic AEs Post-Vaccination 1 | 38.0 | 23.3 | 36.4 | 43.2 |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A systemic AE was defined as any non-injection-site AE. Systemic AEs were recorded on a VRC. The percentage of participants who experienced a systemic AE after Vaccination 2 (up to approximately 42 days post-vaccination) was summarized for all study arms receiving a second vaccination (adults and adolescents).
| Percentage of participants | VARIVAX Adults (18 to 75 Years) | VARIVAX™ Adolescents 13 to 17 Years of Age | VARIVAX™ Children 7 to 12 Years of Age | VARIVAX™ Children 12 Months to 6 Years of Age |
|---|---|---|---|---|
| Percentage of Participants With Systemic AEs Post-Vaccination 2 | 28.6 | 26.7 | — | — |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was an AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or another important medical event. The percentage of participants who experienced one or more SAEs after either vaccination (up to approximately 42 days post-vaccination) was summarized for all study arms.
| Percentage of participants | VARIVAX Adults (18 to 75 Years) | VARIVAX™ Adolescents 13 to 17 Years of Age | VARIVAX™ Children 7 to 12 Years of Age | VARIVAX™ Children 12 Months to 6 Years of Age |
|---|---|---|---|---|
| Percentage of Participants With 1 or More Serious Adverse Events (SAEs) Post-Vaccination 1 or Post-Vaccination 2 | 0.0 | 0.0 | 3.0 | 0.0 |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A vaccine-related SAE was an AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or another important medical event, that was considered at least possibly related to the study vaccine. The percentage of participants who experienced one or more vaccine-related SAEs after either vaccination (up to approximately 42 days post-vaccination) was summarized for all study arms.
| Percentage of participants | VARIVAX Adults (18 to 75 Years) | VARIVAX™ Adolescents 13 to 17 Years of Age | VARIVAX™ Children 7 to 12 Years of Age | VARIVAX™ Children 12 Months to 6 Years of Age |
|---|---|---|---|---|
| Percentage of Participants With Vaccine-Related SAEs Post-Vaccination 1 or Post-Vaccination 2 | 0.0 | 0.0 | 0.0 | 0.0 |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A vaccine-related SAE was an AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or another important medical event, that was considered at least possibly related to the study vaccine. The percentage of participants who experienced a vaccine-related SAE that resulted in death after either vaccination (up to approximately 42 days post-vaccination) was summarized for all study arms.
| Percentage of participants | VARIVAX Adults (18 to 75 Years) | VARIVAX™ Adolescents 13 to 17 Years of Age | VARIVAX™ Children 7 to 12 Years of Age | VARIVAX™ Children 12 Months to 6 Years of Age |
|---|---|---|---|---|
| Percentage of Participants With Vaccine-Related Death Post-Vaccination 1 or Post-Vaccination 2 | 0.0 | 0.0 | 0.0 | 0.0 |
Collected over Adverse Events: Up to 42 days post-Vaccination 1 or post-Vaccination 2 (up to approximately 86 days); All-Cause Mortality: Up to approximately 16 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| VARIVAX Adults (18 to 75 Years) | 0/50 (0%) | 0/50 (0%) | 40/50 (80%) |
| VARIVAX Adolescents (13 to 17 Years) | 0/30 (0%) | 0/30 (0%) | 17/30 (56.7%) |
| VARIVAX Children (7 to 12 Years) | 0/33 (0%) | 1/33 (3%) | 15/33 (45.5%) |
| VARIVAX Children (12 Months to 6 Years) | 0/37 (0%) | 0/37 (0%) | 16/37 (43.2%) |
| Event | VARIVAX Adults (18 to 75 Years) | VARIVAX Adolescents (13 to 17 Years) | VARIVAX Children (7 to 12 Years) | VARIVAX Children (12 Months to 6 Years) |
|---|---|---|---|---|
| HeadacheNervous system disorders | 0/50 | 0/30 | 1/33 | 0/37 |
| Event | VARIVAX Adults (18 to 75 Years) | VARIVAX Adolescents (13 to 17 Years) | VARIVAX Children (7 to 12 Years) | VARIVAX Children (12 Months to 6 Years) |
|---|---|---|---|---|
| Injection site painGeneral disorders | 29/50 | 10/30 | 10/33 | 5/37 |
| Injection site erythemaGeneral disorders | 16/50 | 1/30 | 1/33 | 0/37 |
| Body temperature increasedInvestigations | 6/50 | 5/30 | 2/33 | 9/37 |
| HeadacheNervous system disorders | 9/50 | 6/30 | 5/33 | 0/37 |
| Injection site swellingGeneral disorders | 7/50 | 1/30 | 1/33 | 0/37 |
| Respiratory tract infectionInfections and infestations | 1/50 | 0/30 | 2/33 | 5/37 |
| Respiratory tract infection viralInfections and infestations | 1/50 | 2/30 | 1/33 | 4/37 |
| Rash vesicularSkin and subcutaneous tissue disorders | 3/50 | 0/30 | 2/33 | 1/37 |
| DysmenorrhoeaReproductive system and breast disorders | 3/50 | 0/30 | 0/33 | 0/37 |
| VomitingGastrointestinal disorders | 0/50 | 0/30 | 0/33 | 2/37 |
| Age, Continuous(years) | VARIVAX Adults (18 to 75 Years) | VARIVAX™ Adolescents 13 to 17 Years of Age | VARIVAX™ Children 7 to 12 Years of Age | VARIVAX™ Children 12 Months to 6 Years of Age | Total |
|---|---|---|---|---|---|
| Mean | 24.7 ± 6.0 | 15.1 ± 1.5 | 9.6 ± 1.6 | 3.2 ± 1.6 | 14.2 ± 9.2 |
| Sex: Female, Male(Participants) | VARIVAX Adults (18 to 75 Years) | VARIVAX™ Adolescents 13 to 17 Years of Age | VARIVAX™ Children 7 to 12 Years of Age | VARIVAX™ Children 12 Months to 6 Years of Age | Total |
|---|---|---|---|---|---|
| Female | 36 | 16 | 14 | 18 | 84 |
| Male | 14 | 14 | 19 | 19 | 66 |
| Ethnicity (NIH/OMB)(Participants) | VARIVAX Adults (18 to 75 Years) | VARIVAX™ Adolescents 13 to 17 Years of Age | VARIVAX™ Children 7 to 12 Years of Age | VARIVAX™ Children 12 Months to 6 Years of Age | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 0 | 1 |
| Not Hispanic or Latino | 48 | 30 | 33 | 37 | 148 |
| Unknown or Not Reported | 1 | 0 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | VARIVAX Adults (18 to 75 Years) | VARIVAX™ Adolescents 13 to 17 Years of Age | VARIVAX™ Children 7 to 12 Years of Age | VARIVAX™ Children 12 Months to 6 Years of Age | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 50 | 30 | 33 | 37 | 150 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Serostatus for Varicella-Zoster Virus (VZV)(Participants) | VARIVAX Adults (18 to 75 Years) | VARIVAX™ Adolescents 13 to 17 Years of Age | VARIVAX™ Children 7 to 12 Years of Age | VARIVAX™ Children 12 Months to 6 Years of Age | Total |
|---|---|---|---|---|---|
| VZV Seronegative | 26 | 18 | 22 | 34 | 100 |
| VZV Seropositive | 24 | 12 | 11 | 3 | 50 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Mar 2019 to primary completion in Jun 2020, 15 months.
Results were first posted in Apr 2021, 9 months after primary completion.
Of 35 industry-sponsored phase 3 interventional studies under Chickenpox, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 15. This study's 15 months is above that.
Counting every sponsor, half of 39 studies reached it within 13 months; a quarter within 9 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Chickenpox Vaccine